Journal Scans
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Everolimus Improves PFS in ER+ Advanced Breast Cancer
J Baselga, M Campone, M Piccart, HA Burris III, HS Rugo, T Sahmoud, S Noguchi, M Gnant, KI Pritchard, F Lebrun, JT Beck, Y Ito, D Yardley, I Deleu, A Perez, T Bachelot, L Vittori, Z Xu, P Mukhopadhyay, D Lebwohl, GN Hortobagyi
20111107
2011 Dec 7
N Engl J Med
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
N Engl J Med. 2011 Dec 7;[Epub Ahead of Print], J Baselga, M Campone, M Piccart, HA Burris III, HS Rugo, T Sahmoud, S Noguchi, M Gnant, KI Pritchard, F Lebrun, JT Beck, Y Ito, D Yardley, I Deleu, A Perez, T Bachelot, L Vittori, Z Xu, P Mukhopadhyay, D Lebwohl, GN Hortobagyi
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
Aromatase inhibitors are standard first-line treatment for postmenopausal women with hormone-receptor (HR)–positive advanced breast cancer. However, not all patients respond initially, and those who respond may ultimately relapse. Thus, new therapeutic strategies to enhance the efficacy of endocrine therapy are needed.Resistance to aromatase inhibitors has been linked to activation of the mammalian target of rapamycin (mTOR) intracellular signaling pathway. The mTOR pathway has been shown to interact...
